Cartesian Therapeutics
RNAC

$16.44

0.6%

Market Cap: $352M

About: Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

Employees: 38

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 9 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

50% more capital invested

Capital invested by funds: $56.3M [Q1] → $84.7M (+$28.4M) [Q2]

13% less funds holding

Funds holding: 69 [Q1] → 60 (-9) [Q2]

14.27% less ownership

Funds ownership: 31.91% [Q1] → 17.64% (-14.27%) [Q2]

32% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 28

98% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 40

See Fund Rankings

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$41

149%

upside

Avg. target

$45

172%

upside

High target

$50

204%

upside

9 analyst ratings

9 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Mitchell Kapoor 52% 1-year accuracy 16 / 31 met price target	174%upside $45	Buy Reiterated	13 Sept 2024
HC Wainwright & Co. Mitchell Kapoor 52% 1-year accuracy 16 / 31 met price target	174%upside $45	Buy Reiterated	4 Sept 2024
HC Wainwright & Co. Mitchell Kapoor 52% 1-year accuracy 16 / 31 met price target	174%upside $45	Buy Maintained	12 Aug 2024
Needham Gil Blum 47% 1-year accuracy 67 / 142 met price target	149%upside $41	Buy Maintained	9 Aug 2024
Needham Gil Blum 47% 1-year accuracy 67 / 142 met price target	155%upside $42	Buy Reiterated	8 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about RNAC published over the past 30 days

Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results

Cartesian Therapeutics, Inc.'s Descartes-08 mRNA CAR-T therapy shows promising Phase 2 results for myasthenia gravis without preconditioning chemotherapy. The company's RNA Armory platform enables precise, temporary cell modulation, reducing long-term side effects and avoiding genomic integration. Descartes-08 has received FDA Orphan and RMAT designations, with a Phase 3 trial expected to begin by the end of 2024.

Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results

Cartesian Therapeutics Announces New Employment Inducement Grant

GAITHERSBURG, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to a new employee. On September 3, 2024, the Company issued to this employee an option to purchase 3,864 shares of the Company's common stock with an exercise price of $13.12, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company's board of directors. The option vests as to 25% on September 3, 2025, and then in three equal annual installments thereafter such that the option will be fully vested on September 3, 2028. The option has a ten-year term. The option was granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee's entry into employment with the Company.

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

Descartes-15 observed to achieve an approximately ten-fold increase relative to Descartes-08 in CAR expression and selective target-specific killing in preclinical studies

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

Zacks Investment Research

Cartesian Therapeutics, Inc. (RNAC) Q2 Earnings and Revenues Top Estimates

Cartesian Therapeutics, Inc. (RNAC) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of a loss of $0.81 per share. This compares to loss of $2.10 per share a year ago.

Cartesian Therapeutics, Inc. (RNAC) Q2 Earnings and Revenues Top Estimates

Cartesian Therapeutics Announces New Employment Inducement Grants

GAITHERSBURG, Md., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to seven new employees. On August 1, 2024, the Company issued to these employees options to purchase an aggregate of 100,457 shares of the Company's common stock with an exercise price of $15.47, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. Each of the options vest as to 25% on August 1, 2025, and then in three equal annual installments thereafter such that the options will be fully vested on August 1, 2028. Each of the options has a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee's entry into employment with the Company.

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces New Employment Inducement Grants

GAITHERSBURG, Md., July 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to new employees. On July 1, 2024, the Company issued to these employees options to purchase an aggregate of 35,198 shares of the Company's common stock with an exercise price of $24.27, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. Each of the options vest as to 25% on July 1, 2025, and then in three equal annual installments thereafter such that the options will be fully vested on July 1, 2028. Each of the options has a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employee's entry into employment with the Company.

Cartesian Therapeutics Announces New Employment Inducement Grants

Zacks Investment Research

Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates

Cartesian (RNAC) announced that the phase IIb study in MG patients has achieved its primary endpoints. However, the stock nosedives following an equity financing announcement.

Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates

Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

Dr. Malik to deepen strategic leadership and provide regulatory and clinical development innovation expertise Dr. Malik to deepen strategic leadership and provide regulatory and clinical development innovation expertise

Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data

Cartesian Therapeutics, Inc. achieved positive results from the phase 2b study using Descartes-08 for the treatment of patients with myasthenia gravis; the End of phase 2 meeting with the FDA is expected by the end of 2024. The global market for generalized myasthenia gravis is projected to reach $7.5 billion by 2031. A soon-to-be-initiated phase 2 basket study would explore other autoimmune disorder indications for Descartes-08; The global autoimmune disease therapeutics market is expected to reach $123.5 billion by 2033.

Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data

Investors Business Daily

Cartesian Therapeutics Plummets Despite 'Watershed Moment' For CAR-T Drugs

Cartesian Therapeutics reported a "watershed moment" for its autoimmune-disease drug on Tuesday, but the biotech stock plunged.

Cartesian Therapeutics Plummets Despite 'Watershed Moment' For CAR-T Drugs

See News Rankings